Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting.
Journal
Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937
Informations de publication
Date de publication:
06 May 2024
06 May 2024
Historique:
received:
24
01
2024
accepted:
27
04
2024
medline:
7
5
2024
pubmed:
7
5
2024
entrez:
6
5
2024
Statut:
epublish
Résumé
Currently, many off-the-shelf chimeric antigen receptor (CAR)-T cell products are under investigation for the treatment of relapsed or refractory (R/R) B-cell neoplasms. Compared with autologous CAR-T cell therapy, off-the-shelf universal CAR-T cell therapies have many potential benefits, such as immediate accessibility for patients, stable quality due to industrialized manufacturing and additional infusions of CAR-T cells with different targets. However, critical challenges, including graft-versus-host disease and CAR-T cell elimination by the host immune system, still require extensive research. The most common technological approaches involve modifying healthy donor T cells via gene editing technology and altering different types of T cells. This article summarizes some of the latest data from preclinical and clinical studies of off-the-shelf CAR-T cell therapies in the treatment of R/R B-cell malignancies from the 2023 ASH Annual Meeting (ASH 2023).
Identifiants
pubmed: 38711046
doi: 10.1186/s13045-024-01550-9
pii: 10.1186/s13045-024-01550-9
doi:
Substances chimiques
Receptors, Chimeric Antigen
0
Types de publication
Review
Journal Article
Research Support, Non-U.S. Gov't
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
29Subventions
Organisme : National Natural Science Foundation of China
ID : No.82070124
Organisme : Natural Science Foundation of Hubei Province
ID : No.2020CFA065
Organisme : Fundamental Research Support Program of Huazhong University of Science and Technology
ID : No.5003530166
Informations de copyright
© 2024. The Author(s).
Références
Locke FL, Munoz JL, Tees MT, et al. ALLO-647 for lymphodepletion in the allogeneic CAR T setting: safety experience with ALLO-501/501A in patients (Pts) with relapsed/refractory (r/r) large B-cell and follicular lymphomas. Blood. 2023;142(Suppl 1):2095–2095.
doi: 10.1182/blood-2023-189196
Jain N, Chevallier P, Liu H, et al. Updated results of the phase I BALLI-01 trial of UCART22 process 2 (P2), an anti-CD22 allogeneic CAR-T cell product manufactured by cellectis biologics, in patients with relapsed or refractory (R/R) CD22+ B-cell acute lymphoblastic leukemia (B-ALL). Blood. 2023;142(Suppl 1):4847–4847.
doi: 10.1182/blood-2023-187252
Abramson JS, Ramakrishnan A, Pierola AA, et al. Preliminary results of Nathali-01: a first-in-human phase I/IIa study of UCART20x22, a dual allogeneic CAR-T cell product targeting CD20 and CD22, in relapsed or refractory (R/R) non-hodgkin lymphoma (NHL). Blood. 2023;142(Suppl 1):2110–2110.
doi: 10.1182/blood-2023-186570
Dholaria B, Kocoglu MH, Kin A, et al. Early safety results of P-BCMA-ALLO1, a fully allogeneic chimeric antigen receptor T-Cell (CAR-T), in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2023;142(Suppl 1):3479–3479.
doi: 10.1182/blood-2023-182430
Spehr J, Meyer JE, Loff S, et al. Functional characterization and optimization of switchable allogeneic chimeric antigen receptor T cells for targeting CD19 and CD20 in B cell malignancies. Blood. 2023;142(Suppl 1):2059–2059.
doi: 10.1182/blood-2023-180873
Johnson A, Wright H, Hu X, et al. Hypoimmune, allogeneic CD22-directed CAR T cells that evade innate and adaptive immune rejection for the treatment of large B cell lymphoma patients that are relapsed/refractory to CD19-directed CAR T cell therapy. Blood. 2023;142(Suppl 1):3437–3437.
doi: 10.1182/blood-2023-187096
Hu Y, Wei G, Fu S, et al. Intracellular retention of Tcrαβ/CD3 to generate novel allogeneic CAR-T cells (ThisCART19A) with enhanced antitumor potency for treating B-ALL. Blood. 2023;142(Suppl 1):2111–2111.
doi: 10.1182/blood-2023-189052
Shahid S, Flynn GC, Mauguen A, et al. Long term follow-up after treatment with allogeneic off-the-shelf CAR T cell therapy for relapsed or refractory B-cell malignancies. Blood. 2023;142(Suppl 1):3476–3476.
doi: 10.1182/blood-2023-180753
Cha S, Charbonneau M, Brito A, Habibi A, Pham C, Nguyen C. ATA3431: allogeneic CD19/CD20 bispecific CAR EBV T cells for the treatment of B-cell malignancies. Blood. 2023;142(Suppl 1):4800–4800.
doi: 10.1182/blood-2023-181199
Moreno MA, Kennedy-Wilde J, Wrong AD, et al. Expansion, persistence and pharmacodynamic profile of ADI-001, a first-in-class allogeneic CD20-targeted CAR gamma delta T cell therapy, in patients with relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma. Blood. 2023;142(Suppl 1):3478–3478.
doi: 10.1182/blood-2023-181919
Leong L, Narula M, Heslop HE, Brenner MK, Mamonkin M, Watanabe N. Combining apoptotic resistance and cytokine signaling to improve persistence and anti-tumor activity of CAR Vδ2 T cells in vivo. Blood. 2023;142(Suppl 1):3440–3440.
doi: 10.1182/blood-2023-187658
Hattori Y, Kubo T, Nagano S, et al. Anti-CD38-CAR IPS-derived cytotoxic T lymphocytes efficiently eliminate myeloma cells treated with daratumumab and isatuximab in vitro and in vivo. Blood. 2023;142(Suppl 1):3312–3312.
doi: 10.1182/blood-2023-173356
Xiao X, Lei W, Jiang H, et al. A phase 1 study of RJMty19: anti-CD19 humanized CAR-engineered allogeneic double negative T cells in adults with B-cell non-Hodgkin’s lymphoma. Blood. 2023;142(Suppl 1):2094–2094.
doi: 10.1182/blood-2023-189149